Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma

Surgery

Volumn 147, Issue 3, 2010, Pages 424-431

  Orita, Yorihisa ^a   Sugitani, Iwao ^b   Matsuura, Masaaki ^c   Ushijima, Masaru ^c   Tsukahara, Kiyoaki ^d   Fujimoto, Yoshihide ^b   Kawabata, Kazuyoshi ^b  

^a OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c CANCER INSTITUTE   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADIOISOTOPE THERAPY; SUBTOTAL THYROIDECTOMY; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME;

ADULT; AGED; BONE NEOPLASMS; CARCINOMA; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 76749160633     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.10.009     Document Type: Article

References (32)

1. Do M.Y., Rhee Y., Kim D.J., Kim C.S., Nam K.H., Ahn C.W., et al. Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period. Endocr J 52 (2005) 701-707
2. Sugitani I., and Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 46 (1999) 209-216
3. Sakamoto A., Kasai N., and Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52 (1983) 1849-1855
4. Sugitani I., Kasai N., Fujimoto Y., and Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135 (2004) 139-148
5. Fujimoto Y., and Sugitani I. Postoperative prognosis of intrathyroidal papillary thyroid carcinoma: long-term (35-45 year) follow-up study. Endocr J 45 (1998) 475-484
6. Fujimoto Y., Obara T., Ito Y., Kodama T., Yashiro T., Yamashita T., et al. Aggressive surgical approach for locally invasive papillary carcinoma of the thyroid in patients over forty-five years of age. Surgery 100 (1986) 1098-1107
7. Sugitani I., Kamata S., Kawabata K., Kasai N., and Fujimoto Y. Total pharyngo-laryngectomy and reconstruction of cervical esophagus with a jejunal free flap for locally advanced differentiated thyroid carcinoma. Thyroidol Clin Exp 10 (1998) 249-253
8. Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Eng J Med 338 (1998) 297-306
9. Marcocci C., Pacini F., Elisei R., Schipani E., Ceccarelli C., Miccoli P., et al. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 106 (1989) 960-966
10. Pittas A.G., Adler M., Fazzari M., Tickoo S., Rosai J., Larson S.M., et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty six patients. Thyroid 10 (2000) 261-268
11. Proye C.A., Dromer D.H., Camaille B.M., Gontier A.J., Goropoulos A., Carpentier P., et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?. World J Surg 16 (1992) 640-646
12. Shoup M., Stojadinovic A., Nissan A., Ghossein R.A., Freedman S., Brennan M.F., et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 197 (2003) 191-197
13. Tickoo S.K., Pittas A.G., Adler M., Fazzari M., Larson S.M., Robbins R.J., et al. Bone metastases from thyroid carcinoma. A histopathologic study with clinical correlates. Arch Pathol Lab Med 124 (2000) 1440-1447
14. Schlumberger M., Challeton C., De Vathaire F., Travagli J.P., Gardet P., Lumbroso J.D., et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37 (1996) 598-605
15. Harness J.K., Thompson N.W., McLeod M.K., Eckhauser F.E., and Lloyd R.V. Follicular carcinoma of the thyroid gland: Trends and treatment. Surgery 96 (1984) 972-980
16. 131I-based detection on outcome. Endocr Relat Cancer 14 (2007) 799-807
17. Yamashita H., Fujimoto Y., Kodama T., Hirayama A., Obara T., Ito Y., et al. When is total thyroidectomy indicated as a treatment of "follicular carcinoma"?. World J Surg 12 (1988) 559-564
18. Sugitani I., Fujimoto Y., and Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 143 (2008) 35-42
19. Haq M., and Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol 63 (2005) 87-93
20. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocr Metab 91 (2006) 2892-2899
21. Bernier M.O., Leenhardt L., Hoang C., Aurengo A., Mary J.Y., Menegaux F., et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocr Metab 86 (2001) 1568-1573
22. Koizumi M., and Ogata E. Bone metabolic markers as gauges of metastasis to bone: a review. Ann Nucl Med 16 (2002) 161-168
23. Schlumberger M., Tubiana M., De Vathaire F., Hill C., Gardet P., Travagli J.P., et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63 (1986) 960-967
24. Ito S., Kato K., Ikeda M., Imano S., Makino N., Tadokoro M., et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 48 (2007) 889-895
25. Sugitani I., Yanagisawa A., Shimizu A., Kato M., and Fujimoto Y. Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J Surg 22 (1998) 731-737
26. Hay I.D., Grant C.S., van Heerden J.A., Goellner J.R., Ebersold J.R., and Bergstralh E.J. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112 (1992) 1139-1147
27. Allo M.D., Christianson W., and Koivunen D. Not all "occult" papillary carcinomas are "minimal". Surgery 104 (1988) 971-976
28. Hammerberg K.W. Surgical treatment of metastatic spine disease. Spine 17 (1992) 1148-1153
29. Cascinu S., Graziano F., Alessandroni P., Ligi M., Del Ferro E., Rossi D., et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 6 (1998) 139-143
30. Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., Hirsh V., Krzakowski M., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 (2004) 2613-2621
31. Santini D., Fratto M.E., Vincenzi B., Galluzzo S., and Tonini G. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 6 (2006) 1333-1348
32. Vitale G., Fonderico F., Martignetti A., Caraglia M., Ciccarelli A., Nuzzo V., et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Brit J Cancer 84 (2001) 1586-1590